Announcements Trials

Browse Landscape

Phase

Phase 2 10 Phase 3 4 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma Of Esophagus 1 Adenocarcinoma 1

Interventions

Pemetrexed 13 Carboplatin 13 Docetaxel 11 Cisplatin 11 pembrolizumab 9 Paclitaxel 8 Gemcitabine 7 Erlotinib Hydrochloride 4 Bevacizumab 4 anlotinib 3 Radiotherapy 3 Magnetic Resonance Spectroscopy 3 Gefitinib 3 Dexamethasone 3 dexamethasone acetate 2 dexamethasone 21-phosphate 2 cobimetinib 2 cemiplimab 2 auricularum 2 atezolizumab 2 apatinib 2 Vemurafenib 2 Surgical Procedures, Operative 2 Standard of Care 2 Specimen Handling 2 Ramucirumab 2 Calcium Dobesilate 2 trametinib 1 toripalimab 1 tislelizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Carcinoma, Non-Small-Cell Lung × CP protocol × Clear all

NCT07365319 2026-05-20

TeLuRide-008

Eikon Therapeutics

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡